Human PAK3 Protein (His Tag)
bPAK,CDKN1A,hPAK3,MRX30,MRX47,OPHN3,PAK3beta
- 100ug (NPP4142) Please inquiry
| Catalog Number | P11532-H08B |
|---|---|
| Organism Species | Human |
| Host | Baculovirus-Insect Cells |
| Synonyms | bPAK,CDKN1A,hPAK3,MRX30,MRX47,OPHN3,PAK3beta |
| Molecular Weight | The recombinant human PAK3 consists of 554 amino acids and predicts a molecular mass of 62 kDa. It migrates as an approximately 60 kDa band in SDS-PAGE in SDS-PAGE under reducing conditions. |
| predicted N | Met 1 |
| SDS-PAGE |  |
| Purity | > 97 % as determined by SDS-PAGE |
| Protein Construction | A DNA sequence encoding the human PAK3 isoform 2 (O75914-2) (Met 1-Arg 544) was fused with a polyhistidine tag at the C-terminus. |
| Bio-activity | The specific activity was determined to be 98 nmol/min/mg using MBP as substrate. |
| Research Area | Cancer |Signal transduction |Cytoskeleton / ECM |Extracellular Matrix |Structures |Focal Adhesions | |
| Formulation | Supplied as sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% glycerol 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. |
| Background | PAK3 is a member of PAK proteins, a family of serine/threonine p21-activating kinases, serve as effectors of small Rho GTPases Cdc42 and RAC and have been implicated in a wide range of biological activities. There are six mammalian PAKs which can be divided into two groups: group I PAKs (PAK1-3) and group II PAKs (PAK4-6). Although the two PAK groups are architecturally similar there are differences in their mode of regulation suggesting their cellular functions are likely to be different. Group I p21-activated kinases (PAK1/2/3) is demonstrated as ERK3/ERK4 activation loop kinases. It has been shown that group I PAKs phosphorylate ERK3 and ERK4 on Ser-189 and Ser-186, respectively, both in vitro and in vivo, and that expression of activated Rac1 augments this response. Besides regulation enzymatic activation of ERK3/ERK4, PAKs can also play roles in downstream activation of MAP kinase-activated protein kinase 5 (MK5) in vivo. Thus, the group I PAKs act as upstream activators of ERK3 and ERK4 and unravel a novel PAK-ERK3/ERK4-MK5 signaling pathway. In clinical, PAK has been proposed as a potential therapeutic target in schwannomas. |
| Reference |